Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
AZD5363
Description:
AZD5363, also known as capivasertib, is a small-molecule inhibitor of AKT studied as an anticancer drug.
Primary topic:
PI3K/AKT/mTOR signaling in cancer (38%)
Related topics:
PI3K/AKT/mTOR signaling in cancer (38%),
Prostate Cancer Treatment and Research (11%)
Wikidata ID:
wiki/Q27074756
OpenAlex ID:
keywords/azd5363
Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases
1989
·
Urs T. Rüegg
, Burgess Gillian
·
Trends in Pharmacological Sciences
·
971
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2012
·
Barry R. Davies
, Hannah Greenwood
, et al.
·
Molecular Cancer Therapeutics
·
529
AKT Inhibition in Solid Tumors With AKT1 Mutations
2017
·
David M. Hyman
, Lillian M. Smyth
, et al.
·
Journal of Clinical Oncology
·
332
Discovery of 4-Amino- N -[(1 S )-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7 H -pyrrolo[2,3- d ]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
2013
·
Matt Addie
, Peter Ballard
, et al.
·
Journal of Medicinal Chemistry
·
267
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
2013
·
Eeva M. Sommer
, Hannah Dry
, et al.
·
Biochemical Journal
·
180
PDF
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers
2018
·
Udai Banerji
, Emma J. Dean
, et al.
·
Clinical Cancer Research
·
160
PDF
Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
2013
·
Christian Thomas
, Francois Lamoureux
, et al.
·
Molecular Cancer Therapeutics
·
153
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
2014
·
Paul Toren
, Soojin Kim
, et al.
·
European Urology
·
115
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
2017
·
Tabea Erdmann
, Pavel Klener
, et al.
·
Blood
·
109
PDF
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models
2014
·
Rute B. Marques
, Ashraf Aghai
, et al.
·
European Urology
·
108
Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363
2013
·
Francois Lamoureux
, Christian Thomas
, et al.
·
Clinical Cancer Research
·
105
Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
2019
·
Hannah Tovell
, Andrea Testa
, et al.
·
ACS Chemical Biology
·
96
PDF
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
2016
·
Yan Kong
, Lu Si
, et al.
·
Clinical Cancer Research
·
95
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
2020
·
M.P. Kolinsky
, P. Rescigno
, et al.
·
Annals of Oncology
·
93
PDF
Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation
2013
·
Emily M Fox
, María Gabriela Kuba
, et al.
·
Breast Cancer Research
·
93
PDF
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
2015
·
Ricardo Ribas
, Sunil Pancholi
, et al.
·
Molecular Cancer Therapeutics
·
87
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
2013
·
Jing Li
, Barry R Davies
, et al.
·
Journal of Translational Medicine
·
84
PDF
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
2015
·
Barry R. Davies
, Nin Guan
, et al.
·
Molecular Cancer Therapeutics
·
83
Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363
2017
·
Michael Weller
, Patrick Roth
, et al.
·
JNCI Journal of the National Cancer Institute
·
80
PDF
E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer
2018
·
Katy Teo
, Laura Gómez-Cuadrado
, et al.
·
Scientific Reports
·
74
PDF
Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines
2015
·
Joseph Cursons
, Karl-Johan Leuchowius
, et al.
·
Cell Communication and Signaling
·
71
PDF
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.
2018
·
Peter Schmid
, Jacinta Abraham
, et al.
·
Journal of Clinical Oncology
·
67
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
2016
·
Kenji Tamura
, Jun Hashimoto
, et al.
·
Cancer Chemotherapy and Pharmacology
·
67
PDF
Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment
2021
·
Mariam Mroweh
, Gaël Roth
, et al.
·
International Journal of Molecular Sciences
·
62
PDF
Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis
2019
·
Suguru Kadomoto
, Kouji Izumi
, et al.
·
Cancers
·
62
PDF
Show more works
View as search
Works count:
307
Citation count:
6,102
Year
Topic
Type